

General background text Pharmacogenetics – Methylenetetrahydrofolate reductase (MTHFR)

Last updated: 4 November 2015

Definitions in pharmacogenetics

The **genotype** is the hereditary information about a specific characteristic of an individual. This information is located in the genes, in the DNA that consists of nucleotides. The piece of the DNA that carries information for one specific hereditary characteristic is called a **gene**. The DNA is divided into chromosomes, which usually occur in pairs. This means that an individual has two copies (two **alleles**) of most genes. Each allele is located on one of the chromosomes of a chromosome pair.

The **phenotype** indicates what the final manifestation (phenotypic state) of a certain genotype is. This can involve the functionality of a protein (for example the enzyme or the receptor), but also the physical manifestation of a disease. The phenotype is a result of the genotype that a person possesses, the degree of expression of the gene in question and the combination with environmental factors such as co-medication, diet and disease conditions. Variations can exist in a population within the DNA that encodes a protein. Variations can result in alleles that encode proteins with no or reduced activity. The simplest form of variations are “**single-nucleotide polymorphisms**” (**SNPs**), in which a certain part of a gene differs by only one nucleotide. If a gene variation occurs in at least 1% of the population, then this is referred to as a genetic **polymorphism**. **Wild-type** is the name given to the most common active allele. There can be a number of different polymorphisms for a certain allele.

Altered enzyme activity and clinical consequences

MTHFR is involved in folic acid metabolism. MTHFR converts 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate. 5,10-methylenetetrahydrofolate is required for thymidine nucleotide synthesis. 5-methyltetrahydrofolate is required for conversion of homocysteine to methionine and therefore for protein synthesis.




Figure 1. Folic acid metabolism and the effect of methotrexate (figure from Lopez-Lopez 2013).

MTXPG = methotrexate polyglutamate, DHFR = dihydrofolate reductase, TS = thymidylate synthetase, MTHFR = methylenetetrahydrofolate reductase.

5-CH-THF = 5-methyltetrahydrofolate, 5,10-CH₂-THF = 5,10-methylenetetrahydrofolate, ABCs = ABC transporters, DHF = dihydrofolate, RFC1 = reduced folate carrier, SHMT1 = serine hydroxymethyltransferase 1, SLCs = solute carrier organic anion transporters, THF = tetrahydrofolate.

The MTHFR polymorphisms 677C>T and 1298A>C lead to reduced activity enzyme.

The 677C>T substitution leads to replacement of alanine at position 222 in the enzyme with valine. The resulting enzyme is more thermolabile. The enzyme activity is reduced to 65% and 30% of normal activity in heterozygotes

and homozygotes respectively. The substitution is associated with increased homocysteine plasma concentrations.

The 1298A>C substitution leads to replacement of glutamic acid at position 429 in the enzyme with alanine. The effect on enzyme activity is smaller than for the 677C>T polymorphism. Homozygotes of the 1298C allele have 60% of the standard enzyme activity.

Reduced MTHFR enzyme activity leads to reduced intracellular tetrahydrofolate concentrations.

Methotrexate is converted in the body to methotrexate polyglutamate, which inhibits dihydrofolate reductase which is part of the folic acid cycle (see figure 1). Dihydrofolate reductase converts dihydrofolate to tetrahydrofolate, which is required for purine nucleotide synthesis and after conversion to 5,10-methylenetetrahydrofolate also for synthesis of thymidine nucleotides by thymidylate synthetase. Methotrexate polyglutamate also directly inhibits thymidylate synthetase. Methotrexate toxicity can be reduced by administration of the tetrahydrofolate precursor folic acid.

As both methotrexate and MTHFR influence folic acid metabolism, gene variants that lead to a reduced-activity MTHFR enzyme could influence the effectiveness and toxicity of methotrexate.

Genotyping

The process of genotyping is used to determine the genotype. It indicates which alleles of the gene for MTHFR are present in the tested individual. MTHFR alleles have a name that consists of the nucleotide number followed by the nucleotide change (e.g. 677T for the variant allele and 677C for the wild-type allele of the polymorphism 677C>T).

In addition to being referred to by their nucleotide change, polymorphisms can also be referred to by the amino acid change or by rs number. As all three systems appear in the literature, table 1 shows the nomenclature according to all three of these systems.

Table 1. Overview of the most important MTHFR polymorphisms

Nucleotide polymorphism	rs number	Protein polymorphisms
677C>T	rs 1801133	Ala222Val
1298A>C	rs 1801131	Glu429Ala

The 677C>T polymorphism has a greater effect on enzyme activity than the 1298A>C polymorphism. Moreover, moderate linkage disequilibrium has been observed between the two polymorphisms. Any clinical effects of 1298A>C may therefore not be fully independent of the effects of the 677C>T polymorphism. For these two reasons, the 677C>T polymorphism is more relevant than the 1298A>C polymorphism.

Ethnic variation in prevalence of genotypes and allele frequency

Data on the prevalence of the genotypes and ethnic variation in allele frequency of the most important MTHFR polymorphism 677C>T are given below.

Approximately 8-12% of the Caucasian population are homozygous for the T allele and approximately 40% are heterozygous. This is approximately 8 and 39-42% in the Netherlands. This is equivalent to an allele frequency of 27-29% in the Netherlands.

Greater spread in allele frequencies has been found in the Asian population, ranging from a factor 3 lower to higher than in the Netherlands. The allele frequency in Africans and African Americans is clearly lower than in Dutch people.

Allele frequencies and genotypes per population are given in table 2.

Table 2. Ethnic variation in prevalence of genotypes and allele frequency

Ethnicity	Country	Prevalence of phenotype (%)			Allele frequency (%)
		677CC	677CT	677TT	677T
Caucasian		48-52	40	8-12	19-40
	The Netherlands	50-53	39-42	8	27-29
Asian					9-36
African					5-9

African-American					11
------------------	--	--	--	--	----

Literature

- Goyal RK. MTHFR 677 C>T genotype and adverse outcomes in treatment of childhood ALL: is the jury in? *Pediatr Blood Cancer* 2009;52:316-7.
- Lopez-Lopez E et al. A systematic review and meta-analysis of MTHFR polymorphisms in methotrexate toxicity prediction in pediatric acute lymphoblastic leukemia. *Pharmacogenomics J* 2013;13:498-506.
- Morgan MD et al. MTHFR functional genetic variation and methotrexate treatment response in rheumatoid arthritis: a meta-analysis. *Pharmacogenomics* 2014; 15:467-75.
- Song GG et al. Association of the MTHFR C677T and A1298C polymorphisms with methotrexate toxicity in rheumatoid arthritis: a meta-analysis. *Clin Rheumatol* 2014; 33:1715-24.
- Hagleitner MM et al. The role of the MTHFR 677C>T polymorphism in methotrexate-induced liver toxicity: a meta-analysis in patients with cancer. *Pharmacogenomics J* 2014;14:115-9.
- van Ede AE et al. The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. *Arthritis Rheum* 2001;44:2525-30.
- Fijnheer R et al. Homocysteine, methylenetetrahydrofolate reductase polymorphism, antiphospholipid antibodies, and thromboembolic events in systemic lupus erythematosus: a retrospective cohort study. *J Rheumatol* 1998;25:1737-42.
- Schneider JA et al. Worldwide distribution of a common methylenetetrahydrofolate reductase mutation. *Am J Hum Genet* 1998;62:1258-60.